BST1 and neoplasm: Our group reported that CD157 is expressed in >90% of primary serous epithelial ovarian cancer [42] where high CD157 expression correlates with increased tumor aggressiveness [43], promotes epithelial-to-mesenchymal transition [44] and is an independent prognostic factor for overall survival [45].